MGNX

MACROGENICS INC

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001125345
$3.96 -1.25% $251.7M
High Impact Filing (7/10)4 New Institutional Positions3 Institutional Exits
Vol
Market Cap$251.7M
Cap SizeMicro Cap
Analyst ConsensusBuy (62%)
Inst. Holders50 funds
Inst. Value$73.8M
Inst. Activity4 buys / 3 sells
SEC Reports7
Press Releases2
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001125345·Prev Close $4.01

Recent Activity

Jun 12, 2026 SEC
A mixed institutional cluster formed in MGNX during Q3 2024: 5 smaller managers modestly added ($411K net buying), while
INST-CLUSTER — Impact 6/10
Jun 11, 2026 SEC
Four institutions increased their MGNX positions in Q3 2025 while one reduced, resulting in net buying of approximately
INST-CLUSTER — Impact 3/10
May 19, 2026 Insider
Koenig Scott was granted 22,000 shares
Director
May 19, 2026 Insider
Ferrante Karen Jean was granted 3,750 shares
Director
May 19, 2026 Insider
HURWITZ EDWARD was granted 22,000 shares
Director
May 17, 2026 clinical_trial_readout
Results Pending: lorigerlimab (Phase 2) — Completed 87d ago
Trial: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Cas
May 13, 2026 SEC
MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in line with EPS consens
8-K — Impact 7/10
Inst.
BANK OF AMERICA CORP — ADD
2,401,814 shares ($6.9M)

Price Targets

$6.75 +70.5% upside Strong Buy
Current $3.96 Low $4.00 Median $7.00 High $9.00 4 analysts
$4.00 $9.00

Analyst Ratings

Buy62% buy · 13 analysts
3Strong Buy
5Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Apr 20, 2026 Barclays MAINTAIN Overweight → Overweight
Apr 10, 2026 B. Riley Securities UPGRADE Neutral → Buy
Mar 10, 2026 Barclays MAINTAIN Overweight → Overweight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.26 ▲ +145.2% $-0.70 — $1.71 145% YoY 4
Next Q $-0.31 ▲ +27.3% $-0.68 — $-0.05 -216% YoY 4
Current FY $0.04 ▲ +102.0% $-0.74 — $0.81 103% YoY 2
Next FY $-1.41 ▼ -5.9% $-1.96 — $-0.58 -4138% YoY 3

Latest Reports

MIXED INST-CLUSTER 6/10
A mixed institutional cluster formed in MGNX during Q3 2024: 5 smaller managers modestly added ($411K net buying), while
Jun 12, 2026
NEUTRAL INST-CLUSTER 3/10
Four institutions increased their MGNX positions in Q3 2025 while one reduced, resulting in net buying of approximately
Jun 11, 2026
MIXED Press 6/10
MacroGenics is selling its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfr
May 11, 2026

Top Institutional Holders

FundValueMove
ROYAL BANK OF CANADA—NEAR_EXIT
RENAISSANCE TECHNOLOGIES LLC$8.6MADD
VANGUARD CAPITAL MANAGEMENT LLC$7.7M—
TWO SIGMA INVESTMENTS, LP$7.3MDOUBLED
BANK OF AMERICA CORP$6.9MADD

Recent Insider Trades

DateInsiderTypeValue
May 19, 2026Koenig ScottA$0.00
May 19, 2026Ferrante KarenA$0.00
May 19, 2026HURWITZ EDWARDA$0.00
May 19, 2026Ferrante KarenA$0.00
May 19, 2026Koenig ScottA$0.00
50 institutional holders with $73.8M total value (25,575,169 shares) as of 2026-Q1. Top holders: ROYAL, RENAISSANCE, VANGUARD. Net buying activity: 4 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1ROYAL BANK OF CANADA90$0.000.0%NEAR_EXIT -96.7%
2RENAISSANCE TECHNOLOGIES LLC2,963,559$8.6M11.6%ADD +71.0%
3VANGUARD CAPITAL MANAGEMENT LLC2,653,853$7.7M10.4%—
4TWO SIGMA INVESTMENTS, LP2,527,829$7.3M9.9%DOUBLED +128.7%
5BANK OF AMERICA CORP /DE/2,401,814$6.9M9.4%ADD +30.7%
6MARSHALL WACE, LLP2,025,526$5.9M7.9%ADD +57.7%
7RA CAPITAL MANAGEMENT, L.P.1,864,176$5.4M7.3%—
8WASATCH ADVISORS LP1,559,701$4.5M6.1%TRIM -40.0%
9VANGUARD PORTFOLIO MANAGEMENT LLC1,208,775$3.5M4.7%—
10BlackRock, Inc.1,163,146$3.4M4.6%TRIM -25.1%
11D. E. Shaw & Co., Inc.1,058,424$3.1M4.1%DOUBLED +240.5%
12Connor, Clark & Lunn Investment Management Ltd.867,249$2.5M3.4%—
13CITADEL ADVISORS LLC782,618$2.3M3.1%DOUBLED +187.6%
14MACKENZIE FINANCIAL CORP597,442$1.7M2.3%DOUBLED +187.4%
15SUSQUEHANNA INTERNATIONAL GROUP, LLP452,227$1.3M1.8%—
16NOMURA ASSET MANAGEMENT INTERNATIONAL INC.420,000$1.2M1.6%—
17VANGUARD FIDUCIARY TRUST CO340,089$982.9K1.3%—
18STATE STREET CORP293,687$848.8K1.2%NEAR_EXIT -78.7%
19GOLDMAN SACHS GROUP INC273,478$790.4K1.1%—
20DIMENSIONAL FUND ADVISORS LP251,803$727.3K1.0%ADD +34.1%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
BANK OF AMERICA CORP /DE/ADD1,837,7202,401,814+30.7%$6.9M2026-Q1
MARSHALL WACE, LLPADD1,284,5632,025,526+57.7%$5.9M2026-Q1
MACKENZIE FINANCIAL CORPDOUBLED207,879597,442+187.4%$1.7M2026-Q1
DIMENSIONAL FUND ADVISORS LPADD187,775251,803+34.1%$727.3K2026-Q1
CANADA PENSION PLAN INVESTMENT BOARDTRIM155,200106,400-31.4%$307.5K2026-Q1
Universal- Beteiligungs- und Servicegesellschaft mbHNEAR_EXIT300,00010,000-96.7%$28.9K2026-Q1
HRT FINANCIAL LPTRIM190,09554,733-71.2%$158.002026-Q1
CWM, LLCNEAR_EXIT992243-75.5%—2025-Q4
RENAISSANCE TECHNOLOGIES LLCADD1,701,2232,908,631+71.0%$4.7M2025-Q4
BANK OF AMERICA CORP /DE/DOUBLED209,4461,837,720+777.4%$3.0M2025-Q4
MARSHALL WACE, LLPDOUBLED629,5351,284,563+104.0%$2.1M2025-Q4
BlackRock, Inc.TRIM1,538,6941,152,649-25.1%$1.9M2025-Q4
TWO SIGMA INVESTMENTS, LPDOUBLED437,091999,474+128.7%$1.6M2025-Q4
D. E. Shaw & Co., Inc.DOUBLED222,200756,647+240.5%$1.2M2025-Q4
Universal- Beteiligungs- und Servicegesellschaft mbHADD210,000300,000+42.9%$468.0K2025-Q4
DIMENSIONAL FUND ADVISORS LPTRIM345,582187,775-45.7%$302.1K2025-Q4
MORGAN STANLEYNEAR_EXIT989,233161,016-83.7%$259.2K2025-Q4
PANAGORA ASSET MANAGEMENT INCDOUBLED61,200150,061+145.2%$241.6K2025-Q4
Invesco Ltd.ADD84,453111,121+31.6%$178.9K2025-Q4
Russell Investments Group, Ltd.NEAR_EXIT49,1051,277-97.4%$2.1K2025-Q4
NISA INVESTMENT ADVISORS, LLCTRIM499347-30.5%$559.002025-Q4
WASATCH ADVISORS LPTRIM3,251,0221,950,287-40.0%$3.3M2025-Q3
RENAISSANCE TECHNOLOGIES LLCADD1,326,4941,701,223+28.2%$2.9M2025-Q3
MORGAN STANLEYDOUBLED446,222989,233+121.7%$1.7M2025-Q3
MARSHALL WACE, LLPADD405,911629,535+55.1%$1.1M2025-Q3
16 unique insiders with 50 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 19, 2026Koenig ScottDirectorAWARD22,000——
May 19, 2026Ferrante Karen JeanDirectorAWARD3,750——
May 19, 2026HURWITZ EDWARDDirectorAWARD22,000——
May 19, 2026Ferrante Karen JeanDirectorAWARD22,000——
May 19, 2026Koenig ScottDirectorAWARD3,750——
May 19, 2026STUMP DAVID CDirectorAWARD3,750——
May 19, 2026STUMP DAVID CDirectorAWARD22,000——
May 19, 2026HURWITZ EDWARDDirectorAWARD3,750——
May 19, 2026Chhabra MeenuDirectorAWARD22,000——
May 19, 2026Chhabra MeenuDirectorAWARD3,750——
May 19, 2026Liu MargaretDirectorAWARD22,000——
May 19, 2026Liu MargaretDirectorAWARD3,750——
May 19, 2026HEIDEN WILLIAM KDirectorAWARD3,750——
May 19, 2026HEIDEN WILLIAM KDirectorAWARD22,000——
May 19, 2026Jackson Scott ThomasDirectorAWARD3,750——
May 19, 2026Jackson Scott ThomasDirectorAWARD22,000——
May 19, 2026O'Brien Federica F.DirectorAWARD22,000——
May 19, 2026O'Brien Federica F.DirectorAWARD3,750——
May 18, 2026SIEGEL JAY PHILIPDirectorEXERCISE3,750——
May 18, 2026Ferrante Karen JeanDirectorEXERCISE3,750——
May 18, 2026HEIDEN WILLIAM KDirectorEXERCISE3,750——
May 18, 2026Jackson Scott ThomasDirectorEXERCISE3,750——
May 18, 2026STUMP DAVID CDirectorEXERCISE3,750——
May 18, 2026HURWITZ EDWARDDirectorEXERCISE3,750——
May 18, 2026Chhabra MeenuDirectorEXERCISE3,750——
May 18, 2026Liu MargaretDirectorEXERCISE3,750——
May 18, 2026O'Brien Federica F.DirectorEXERCISE3,750——
Feb 15, 2026Smith Beth AnnVP, Controller & TreasurerEXERCISE1,095——
Feb 15, 2026Smith Beth AnnVP, Controller & TreasurerTAX W/H423$1.71$723.33
Feb 15, 2026Karrels JamesSVP and CFOEXERCISE14,999——
Feb 15, 2026Karrels JamesSVP and CFOTAX W/H5,790$1.71$9.9K
Feb 15, 2026Peters Jeffrey StuartSenior VP, GC, and SecretaryEXERCISE13,332——
Feb 15, 2026Peters Jeffrey StuartSenior VP, GC, and SecretaryTAX W/H5,147$1.71$8.8K
Feb 15, 2026Spitznagel ThomasSr VP, Technical OpsEXERCISE13,332——
Feb 15, 2026Spitznagel ThomasSr VP, Technical OpsTAX W/H5,520$1.71$9.4K
Feb 15, 2026Risser Eric BlasiusPresident and CEOEXERCISE16,665——
Feb 15, 2026Risser Eric BlasiusPresident and CEOTAX W/H6,433$1.71$11.0K
Feb 15, 2026Koenig ScottDirectorEXERCISE21,165——
Feb 15, 2026Bonvini EzioSr VP, Research & CSOEXERCISE16,665——
Feb 15, 2026Bonvini EzioSr VP, Research & CSOTAX W/H6,433$1.71$11.0K
Feb 12, 2026Smith Beth AnnVP, Controller & TreasurerAWARD15,625——
Feb 12, 2026Smith Beth AnnVP, Controller & TreasurerAWARD93,750——
Feb 12, 2026Karrels JamesSVP and CFOAWARD150,000——
Feb 12, 2026Karrels JamesSVP and CFOAWARD25,000——
Feb 12, 2026Peters Jeffrey StuartSenior VP, GC, and SecretaryAWARD150,000——
Feb 12, 2026Peters Jeffrey StuartSenior VP, GC, and SecretaryAWARD25,000——
Feb 12, 2026Spitznagel ThomasSr VP, Technical OpsAWARD25,000——
Feb 12, 2026Spitznagel ThomasSr VP, Technical OpsAWARD150,000——
Feb 12, 2026Risser Eric BlasiusPresident and CEOAWARD100,000——
Feb 12, 2026Risser Eric BlasiusPresident and CEOAWARD595,000——
7 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.4/10.
MIXED INST-CLUSTER 6/10
A mixed institutional cluster formed in MGNX during Q3 2024: 5 smaller managers modestly added ($411
Jun 12, 2026
NEUTRAL INST-CLUSTER 3/10
Four institutions increased their MGNX positions in Q3 2025 while one reduced, resulting in net buyi
Jun 11, 2026
BULLISH 8-K 7/10
MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in l
May 13, 2026
BULLISH 8-K 7/10
MacroGenics entered into a definitive agreement to sell its GMP manufacturing operations (CDMO busin
May 12, 2026
BULLISH 8-K 7/10
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study
Apr 8, 2026
NEUTRAL DEFA14A 2/10
MacroGenics Inc. has filed a definitive proxy statement for an upcoming shareholder meeting, which i
Apr 8, 2026
BULLISH INST-CLUSTER 6/10
Three major institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly increased
Feb 28, 2026
MIXED 6/10
MacroGenics is selling its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a
May 11, 2026
BULLISH 7/10
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study
Apr 8, 2026
Current analyst consensus: Buy (62% buy). Based on 13 analysts: 3 strong buy, 5 buy, 5 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$6.75 mean target +70.5% upside Strong Buy (3.00)
$4.00 Low $9.00 High
MetricValue
Current Price$3.96
Target Low$4.00
Target Mean$6.75
Target Median$7.00
Target High$9.00
# Analysts4
RecommendationStrong Buy (3.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.26 $-0.70 $1.71 145.2% +145.2% 0↑ 1↓ $0.1B 165.9% 4
Next Q
2026-09-30
 $-0.31 $-0.68 $-0.05 -215.7% +27.3% 0↑ 1↓ $0.0B -54.9% 4
Current FY
2026-12-31
 $0.04 $-0.74 $0.81 103.0% +102.0% 0↑ 1↓ $0.2B 10.0% 2
Next FY
2027-12-31
 $-1.41 $-1.96 $-0.58 -4138.1% -5.9% — $0.1B -42.7% 3

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.258
7d ago$-0.333+0.590
30d ago$-0.570+0.827
60d ago$-0.420+0.677
90d ago$-0.665+0.923
2 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Apr 20, 2026 Barclays MAINTAIN Overweight Overweight
Apr 10, 2026 B. Riley Securities UPGRADE Neutral Buy
Mar 10, 2026 Barclays MAINTAIN Overweight Overweight

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263550062%
May 1, 20263550062%
Apr 1, 20263460054%
Mar 1, 20263460054%
Feb 1, 20263460054%
Jan 1, 20263460054%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 23, 2026
Clinical Trial
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase Phase 2 — COMPLETED
May 17, 2026
clinical_trial_readout
Results Pending: lorigerlimab (Phase 2) — Completed 87d ago
Trial: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Sponsor: MacroGe
May 14, 2026
announcement
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
<p align="justify">ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developi
May 13, 2026
earnings_calendar
MGNX Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
short_volume
Short Volume: MGNX — 69.8% short (2.6M / 3.7M)
Short: 2,590,539 | Exempt: 34,849 | TRF Vol: 3,709,808 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 11, 2026
announcement
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
<p>•MacroGenics to receive $122.5 million upfront payment from Bora upon closing<br>•Transaction includes transfer of manufacturing site, CDMO operati
May 4, 2026
announcement
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-
Apr 17, 2026
clinical_trial_readout
Results Pending: lorigerlimab (Phase 2) — Completed 57d ago
Trial: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Sponsor: MacroGe
Apr 8, 2026
announcement
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
<p>• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers  </p>
Mar 9, 2026
earnings
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
<p align="left">ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focu